Correlation of immune cell activities and β-endorphin release in breast carcinoma patients treated with galactose-specific lectin standardized mistletoe extract

Anticancer Research

Volumn 18, Issue 1 B, 1998, Pages 583-586

  Heiny, Bernd Michael ^a   Albrecht, Valentina ^a   Beuth, Josef ^b  

^a Oncological Department   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

Author keywords

endorphin plasma level; Breast carcinoma patients; Correlation; Immune cell activity; Mistletoe lectin 1

Indexed keywords

BETA ENDORPHIN; GALACTOSE; HLA DR ANTIGEN; INTERLEUKIN 2 RECEPTOR; VISCUM ALBUM LECTIN;

ADULT; ANTIGEN EXPRESSION; ARTICLE; BLOOD LEVEL; BREAST CARCINOMA; CELLULAR IMMUNITY; CLINICAL ARTICLE; FEMALE; HUMAN; NATURAL KILLER CELL; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SUBCUTANEOUS DRUG ADMINISTRATION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADULT; BETA-ENDORPHIN; BREAST NEOPLASMS; HUMANS; IMMUNITY, CELLULAR; KILLER CELLS, NATURAL; MISTLETOE; PLANT PREPARATIONS; PLANT PROTEINS; PLANTS, MEDICINAL; T-LYMPHOCYTES; TOXINS, BIOLOGICAL;

EID: 0031922838     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Heiny BM, Beuth J: Mistletoe extract standardized for the galactoside-specific lectin (ML-1) induces β-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res 14: 1339-1342, 1996.
2. Lenartz D, Herrmann S, Pietsch T, Rommel T, Menzel J, Beuth J: Cytotoxic activity of the galactoside-specific lectin from mistletoe on anaplastic glioma cell spheroids and cell cultures. Z Onkol/J of Oncol 29: 11-15, 1997.
3. Beuth J, Ko HL, Gabius H-J, Pulverer G: Influence of treatment with the immunomodulatory effective dose of the β-galactoside-specific lectin from mistletoe on tumor colonization in BALB/c-mice for two experimental tumor models. In vivo 5: 29-32, 1991.
4. Beuth J, Ko HL, Tunggal L, Steuer MK, Geisel J, Jeljaszewicz J, Pulverer G: Thymocyte proliferation and maturation in response to galactoside-specific mistletoe-lectin-1. In vivo 7: 407-410, 1993.
5. Stoffel B, Kramer K, Mayer H, Beuth J: Immunomodulating efficacy of combined administration of galactoside-specific lectin standardized mistletoe extract and sodium selenite in BALB/c-mice. Anticancer Res 17: 1893-1896, 1997.
6. Stoffel B, Beuth J, Pulverer G: Effect of immunomodulation with galactoside-specific mistletoe lectin on experimental listeriosis. Zbl Bakt 284: 439-442, 1996.
7. Lenartz D, Stoffel B, Menzel J, Beuth J: Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Res 16: 3799-3802, 1996.
8. Beuth J, Gabius H-J, Steuer MK, Geisel J, Steuer M, Ko HL, Pulverer G: Einfluβ der Misteltherapie auf den Serumspiegel definierter Serumproteine (Aktuphaseproteine) bei Tumorpatienten. Med Klinik 88: 287-290, 1993.
9. Beuth J, Stoffel B and Pulverer G: Mistlestoe lectins: Clinically relevant immunomodulators. Acta Nova Leopoldina 301: 89-94, 1997.
10. Beuth J: Clinical relevance of immunomodulating mistletoe lectin-1. Anti Cancer Drugs 8: 53-55, 1997.
11. Ader R, Cohen N, Felten DJ: Brain, behaviour and immunity. Brain Behav Immun 1. 1-9, 1987.
12. Solomon GF: Psychoimmunology: Interactions between central nervous system and immune system. J Neuroscience Res 18: 1-9, 1987.
13. Heijnen CJ, Kavelaars A, Ballieux RE: Betaendorphin: cytokin and neuropeptide. Immunol Rev (Denmark) 119: 41-63, 1991.
14. Falconer J, Chan EC, Madsens G: Secretion of betaendorphins into the maternal circulation by uteroplacental tissue in response to stress. J Endocrinol 118: 5-8, 1988.
15. Kao PC, Heser D: Development of human beta-endorphin radioimmunoassay with synthetic peptide. Clin Chem 26: 961, 1980.
16. Yamagushi HA, Liotta S, Krieger DT: Simultaneous determination of human plasma lipotropin, gamma lipotropin, and beta-endorphin utilizing immune-affinity chromatography. J Clin Endocrin Metab 51: 1002-1008, 1980.
17. Beuth J, Ko HL, Gabius H-J, Pulverer G: Determination of lectin-dependent alteration of cellular parameter by immunophenotyping during adjuvant lectin application. In: Gabius H-J, and Gabius S (eds) Lectins in glycobiology. SpringerVerlag, Berlin, 1993, 396-401.
18. Strauman TJ, Lemieux AM, Coe CL: Self-discrepancy and natural killer cell activity. Immunological consequences of negative self-evalutation. J Pers Soc Psychol 64: 1042-1052, 1993.
19. Homo-Delarche F, Dardenne M: The neuroendocrine-immune axis. Springer Semin Immunopath 14: 221-238, 1993.
20. Adams F, Quesada R: CNS-immunsystem interactions: Conditioning phenomena. Brain Behav Immun 252: 938-944, 1984.
21. Denicoff KD, Durkin TM, Rosenberg SA: The neuroendocrine effects of 1-2 treatment. J Clin Endocrin Metab 69: 402-410, 1989.
22. Blalok JE: The immune system as a sensory organ. J Immunol 132: 1067-1070, 1984.
23. Riley V: Psychoneuroendocrine influences on immunocompetence and neoplasia. Science 212: 1100-1109, 1981.
24. Vescovi PP, Gerra S, Piois S, Passen M: Circulating opioid peptides during thermal stress. Horm Metab Res 22: 44-46, 1990.
25. Levy SM: Biological mediators of behaviour and disease. In: Levy SM (ed); Neoplasia. Elsevier, NewYork 1982, 223-236.